

# Contents

---

## Section 1: R&D Spending

### *Pharmaceuticals*

Trends in Worldwide Pharma and Biotech R&D Expenditures, 2002-2012P (EvaluatePharma)	1
Global R&D Spending by World's Top 400 Pharma and Biotech Companies 2002-2012 (EvaluatePharma)	1
R&D Spending by Research-Based Pharmaceutical Companies, 1980-2007	2
R&D Investments by Research-Based Pharmaceutical Companies, 1975-2007	2
Industry-wide and Government R&D Spending, 1980-2007	3
Biopharmaceutical Industry Investment in Research and Development, 1980-2007	3
Biopharmaceutical R&D Expenditure and NIH Budget: 1995-2007	3
Booz Allen Hamilton Study on R&D Spending	3
Analysis of Top 20 Companies by 2007 Pharma R&D Spend (EvaluatePharma)	4
Top 20 Companies by Pharma R&D Spend in 2007 (EvaluatePharma)	4
Top 20 Companies by Pharma R&D Spend as a % of Pharmaceutical Revenues (EvaluatePharma)	4
Top 20: Average R&D Spend per Late-Stage Project (EvaluatePharma)	4
Total PhRMA R&D as a Percent of Sales, 1985-2007	5
Domestic U.S. R&D and R&D Abroad, 1985-2007	5
Domestic U.S. Sales and Sales Abroad, 1985-2007	5
Growth in Domestic U.S. R&D and R&D Abroad, 1970-2007	6
R&D Spending at Top 50 Pharmaceutical Companies in 2007	7
Productivity as Measured by R&D Spending per NME Approval "Deeply Flawed"	7
Various Measures of New Drug/Biologic R&D Productivity	8
Industry R&D Spending per NDA Submission in the U.S., 1993-2007	8
Industry R&D Spending per NDA Approval in U.S, 1996-2007	8
Industry R&D Spending per NME Submission to FDA, 1995-2007	8
Industry R&D Spending per NME Approved in the U.S., 1995-2007	8
Global R&D Spending per Global New Active Substance (NAS) Launch, 1995-2007	8
Comparative R&D Spending, Sales, and Product Launch Trends Worldwide: A 2008 Analysis	9
Breakdown of World Pharma Market—2007 Sales	9
Pharmaceutical R&D Expenditure Annual Growth Rate, US vs. Europe, 1993-2007	9
Pharmaceutical R&D Expenditure in Europe, the United States, and Japan, 1990-2007	9
Opening and Closing of Research Sites in Europe, US, and Asia, 2001-2006	9
Number of Compounds in Development by Country/Region: U.S., Europe, Japan, and Rest of World	10
U.S., European, Canadian, Japanese and Australian Biotech: Global Activity Measures, 2007	10
An Analysis of Pharma and Biotech Industry R&D Spending Growth Through 2008	11
Pharma R&D Spending, 2003-2008: Trailing 12-Month R&D Spending by Top Pharma and Biotech Companies	11
Pharma M&A Activity in 2007	12
R&D Spending by Geographic Area, Ethical Pharmaceuticals, PhRMA Member Companies, 2006	13
Domestic U.S. Scientific, Professional, and Technical R&D Personnel by R&D Function,	
Ethical Pharmaceuticals, 2006	14
Domestic R&D by Function, Ethical Pharmaceuticals, PhRMA Member Companies, 2006	14
Domestic R&D and R&D Abroad for Human-Use and Veterinary-Use Pharmaceuticals,	
PhRMA Member Companies, 2006	14
Domestic R&D by Origin of Product (Licensed-in vs. Self-originated), PhRMA Member Companies, 2006	14
Phase 4 Postmarketing Research to Top \$12 Billion in 2007—Cutting Edge	14
U.S. Government (NIH) Funding for Medical/Clinical Research, 1995-2008	15
NIH Appropriations, 1995-2009P	15
NIH Clinical Research and Clinical Trials Spending, 2003-2009P	15
Estimates of Funding for Selected Diseases, Conditions, and Research Areas, 2004-2008E	15
Growth in Domestic U.S. Sales and Sales Abroad, Ethical Pharmaceuticals, 1970-2007	16

Sales by Geographic Area, Ethical Pharmaceuticals, PhRMA Member Companies, 2006 .....	17
A New Look at the Global Pharmaceutical Market: North America Sets Pace in 2007 Pharma Sales .....	18
Global Pharma Sales, 1999-2007 .....	18
Global Pharmaceutical Sales in 2007 by Region .....	18
Leading Therapy Classes in 2007 Global Pharma Sales .....	18
Global Pharma Sales in 2007—Leading Products .....	18
Pharma Market Growth in Five Key Regions, 2008 .....	19
Contribution to Drug Market by Age of Drug .....	19
Percentage Contribution to the Overall Market by Age of Drug, 2001-2011E .....	19
Top 20 Companies by Worldwide Prescription Drugs Sales in 2006/2007 (EvaluatePharma) .....	19
An Analysis of Worldwide Prescription and OTC Sales by Technology (2002-2012):	
Biotech vs. Conventional Technology (EvaluatePharma) .....	20
Worldwide Prescription & OTC Sales by Technology, 2002-2012 (EvaluatePharma) .....	20
Top 100 Drug Sales by Technology, 2007-2012 (EvaluatePharma) .....	20
Two in Ten New Drugs Recoup Costs—New Study (EvaluatePharma) .....	20
An Analysis of the Sales Potential of New Drugs Approved in 2006 and 2007 (EvaluatePharma) .....	21
FDA Approval Count vs. 5th Year after Launch US Product Sales (EvaluatePharma) .....	21
Top 10 New Molecular Entities in 2007: Ranked on US Consensus Sales in 2012 (EvaluatePharma) .....	21
Top 10 New Molecular Entities in 2006: Ranked on US Consensus Sales in 2011 (EvaluatePharma) .....	21
Few Drug Launches Vastly Successful—IMS Health .....	21
Biologic Drugs/Vaccine Sales to 2011E .....	22
The Future Pharma R&D Model: The New PharmaCo Threat .....	22
An Analysis of the U.S. Pharma Market: U.S. Prescription Drug Sales in 2007 .....	23
Annual Growth Rate of U.S. Prescription Pharmaceutical Market, 1994-2012P .....	23
Top 10 Therapeutic Classes by U.S. Prescription Sales, 2007 .....	23
Top 10 U.S. Prescription Products by Sales, 2007 .....	23
Top 10 Pharma Companies by U.S. Prescription Sales, 2007 .....	24
Your Own Lab—Oh, and a Home Mortgage .....	24
Want To Help Reduce Healthcare Costs? Then Smoke and Overeat! .....	24
Pharma Behind Networking and Mining/Oil Production Among Most Profitable U.S. Industries .....	24
Global and US Sales Growth of Branded Drugs by Therapeutic Category, 2004-2011E .....	25
Global Drug Sales and Growth Forecasts in Major Therapeutic Areas: 2004-2011E .....	25
US Sales and Growth Forecasts—Major Therapeutic Areas, 2004-2011E .....	26
Therapeutic Categories: Drug Sales as a Percentage of Worldwide Market, 2007 vs. 2012P .....	26
Pharma Companies: Drug Sales as Percentage of Worldwide Market, 2007 vs. 2012P .....	26
The Future of Pharma: Adjusting the Pharma R&D Model .....	27
An Opportunity Map for Pharma R&D .....	27
Large Rx Players Competing for the Same Real Estate .....	28
Assessing Patent Risk: Industry and Company-specific Exposure to Generics, 2006-2011E .....	29
Percentage of US Market Over Time at Risk of Loss Through Patent Expiries, 2000-2013E .....	29
Pharma Sales in 2007E at Risk of Generic Competition in 2008-2012E as a	
Percentage of Pharma Sales at 13 Large Pharma Companies .....	30
Biomarker Market to \$12.8bn by 2012 .....	30
U.S. Generic Drug Market Outlook to 2012 .....	31
2007 U.S. Sales of Drugs Losing Patent Protection, 2008-2012 .....	31
Percent Sales Vulnerable to Patent Expirations Through 2012: Selected Leading Companies .....	31
Prescription Drugs Represent 10% of Health Care Dollar Spent—CMS Analysis .....	31
U.S. Disease Foundation Investment in Biopharma R&D Rises .....	31
New Global Pharma Outsourcing Market Model to 2011 .....	32
CRO Market Opportunity, 2006E-2011E .....	32
CRO Market Opportunity by Stage .....	32
The Goldman Sachs Global R&D Outsourcing Model .....	32
A May 2008 Update to the Goldman Sachs Global R&D Outsourcing Model .....	34
EDC Spending to Top \$500 Million in 2009—Health Industry Insights .....	34
The CRO Contribution to Drug Development: A 2005 Assessment .....	35
Global Spending on Development and Clinical Outsourcing Services, 2001-2004 .....	35
Global Clinical Research Personnel, Pharma Companies vs. CROs, 2001-2004 .....	35
Clinical Study Activity Managed Worldwide by Major CROs, 2001-2004 .....	35
Days That Actual Submission Exceeded Projected Submission Data, Low vs. High CRO Usage Projects .....	35

Mean Time to Four Pivotal Clinical Trial Milestones, Low vs. High CRO Usage Projects	36
A Measure of Quality: Case Report Form Queries/Page Screen	36
Percentage of Development Budget Outsourced, As Average by Phase Across Therapeutic Areas	36
Percentage of Clinical Development Budget Outsourced, as Average Across Therapeutic Areas (by Phase, US)	36
Sources of Clinical Trial Funding, 2001-2007P	36
Breakdown of Government vs. Industry-Sponsored Clinical Trials	36

### *Biopharmaceuticals*

Top 100 Biotech Companies by 2007 R&D Spending	37
R&D Spending at Selected Leading Biotechnology Companies, 2007A-2012E	38
Biotech Industry Benchmarks from E&Y	38
Biotech R&D Spending to 2009E	39
Annual Biotechnology R&D Spending, 2004-2009E	39
Biologics and Biotech R&D: An Analysis of PhRMA Member Companies, 2006	39
Biologics and Biotechnology R&D, PhRMA Member Companies, 2006	39
mAb Sales Growth to Dwarf Small Molecules	39
Financial Markets Continue to Fuel Biotech's R&D Efforts	40
Total Equity Raised by Biotech, 1995-2007	40
Does Biotech Have the Pharma Flu?	40
An Analysis of Global Biologics/Biotech Market: Worldwide Sales for Top Products and Top Product Classes in 2007	41
Top-Selling Categories of Biologic Products, 2007	41
Growth Rates of Top-Selling Classes of Biological Products, 2007	41
Top 20 Selling Biologic Products Worldwide, 2007	41

## **Section 2: Products in Development**

### *Pharmaceuticals*

Worldwide Drugs in the Pipeline by Therapeutic Category as of January 2008 (IMS Health)	43
Top 50 Drug Companies by Number of Drug Products in Development as of January 2008 (IMS Health)	44
Top 50 Drug Companies by Number of Drug Products in Development as of March 2008 (Pharmaprojects)	45
A Snapshot of the Pharma R&D Pipeline, Number of Projects by Development Phase, 1998-2008	46
Worldwide Active R&D Projects in Development by Stage, 1998-2008	46
The R&D Pipeline, 1998-2008	46
An Analysis of the Drug and Biotech Pipeline by Development Phase, Technology, Therapeutic Category, and Strategy (EvaluatePharma)	47
R&D Project Count by Current Phase (EvaluatePharma)	47
R&D Project Count by Technology (EvaluatePharma)	47
R&D Project Count by Therapy Area (EvaluatePharma)	47
R&D Project Count by Strategy, Organic, Licensed (EvaluatePharma)	47
Pipeline Expansion Accelerates	48
Drugs in Active Development, 1995-2008	48
Drug Development by World Status, 1995-2008	48
A 2008 Analysis of the Mid- and Late-Stage R&D Pipeline: Size, Developer Type, Indications, and Success Rates	49
Number of Drugs in Phase 2-Pre-Registration by Developer Type	49
Number of Indications per Drug in Phase 2-Pre-Registration by Developer Type for Select Years	49
Likelihood of Approval by Phase for Large Company Products	49
Likelihood of Approval by Phase for Small Company/Institution Products	49
Wall Street No Longer Impressed by Pipeline	49
Top 20 Most Valuable R&D Projects (Ranked by Net Present Value)	50
Biotech's Responsible for 65% of Recent FDA New Drug Approvals—New Study	50
Valuing Company R&D Pipelines based on NPV Analysis: Top R&D Spenders	51
Valuing the R&D Pipeline based on NPV Analysis	51
Measures of Pharma Industry's New Drug Output: NME/NAS Submissions to FDA and EMEA, 1995-2007	52
Annual Number of Marketing Applications for New Molecular Entities/New Active Substances Filed With the FDA and EMEA, 1995-2007	52
Active Clinical Drug Development Programs Worldwide by Phase, April 2008	53
Number of Active Clinical Development Programs, 2008	53
Total Average Number of Active Programs by Year, March 2002-April 2008	53
Comparison of Annual Growth Rate—2006 vs. 2007 vs. 2008	53

An Analysis of New US Clinical Trial Starts for Drugs as Measured by Commercial IND Submissions to FDA, 2007 .....	54
New US Clinical Trial Starts for Drugs and Biologics/Biotechs, 1998-2007 .....	54
Breakdown of CDER Divisional Workload by INDs Received in 2007 .....	54
Segmentation of US Clinical Trial Starts for Drugs by Therapeutic Category, 2006 and 2007 .....	55
Global New Active Substance Product Launches, 2007 .....	55
An Analysis of U.S.-based Clinical Trial Activity for Drugs as Measured by Active INDs at Year-End 2007 .....	56
Breakdown of CDER Drug Divisions' IND Review Workload (Active as of Year-End 2007) .....	56
Segmentation of US Clinical Trials for Drugs by Therapeutic Category, 2007 .....	56
Top Therapeutic Categories by Number of Projects in Development as of March 2008 (Pharmaprojects) .....	57
Number of Drugs in Preclinical Testing, 1995-2008 (Pharmaprojects) .....	57
Top Therapeutic Drug Categories Worldwide by Number of Projects in Development as of January 2008 .....	57
Drug R&D Projects: Top Ten Areas of Research, 2007 .....	57
The Late-Stage Pipeline: A 2008 Assessment .....	58
New Molecular Entities in Development at Major Pharmaceutical Organizations, 2004 vs. 2006 vs. 2007 .....	58
U.S. Clinical Development Pipeline by Phase, 1997-2007 .....	58
Did the Molecular Bulge Begin Shifting in Late 2007? .....	58
New Compounds in Various Stages of Development, Indexed, 1995-2007 .....	58
New Compounds in Pharmaceutical Development, January 2005-October 2007 .....	58
Proportion of Top Pharma and Biotech Company Pipelines In-Licensed: A 2008 Assessment .....	59
Leading Pharma Companies by Pipeline Size: Percent of Pipelines In-Licensed .....	59
Selected Leading Biotech Companies by Pipeline Size: Percent of Pipelines In-Licensed .....	59
Number of Companies in Pharma R&D on Rise, 1997-2007 .....	59
The R&D Pipeline for Antibody-Derived Therapies, 2006-2012 .....	59
The Future Pharma R&D Model: The NewPharmaCo Threat .....	60
The Pipeline and the New Realities of Drug Development .....	60
Pharma/Biotech Dealmaking: A 2008 Analysis .....	61
Increasing Cost of In-Licensing .....	61
Up-Front Payments Stable in Relative Terms, 2003-2007 .....	62
Deals by Therapy Area, 2007 .....	62
Early-Stage Discovery Deals by Therapy Area, 2007 .....	63
Deals Signed by Stage of Development, 2007 .....	63
Dealmaking Trends: Can Prices Continue to Grow? .....	64
Stingy Public Markets, 2005-2007 .....	64
Average Acquisition Values are Rising, 2000-2007 .....	64
Acquisitions of Recently Public Companies: Valuable....but Rare .....	64
Buying Discovery, 2000-2007 .....	65
Phase II Deal Numbers and Values Increase .....	65
Up-Fronts for Phase III/NDA-Stage Compounds Grow Slightly in 2007 .....	65
Pharma and Biotech Company Pipelines: An Assessment of "Replacement Power," 2007 .....	66
Large Pharma Replacement Power: 13 Major Companies .....	66
Large Biotech Replacement Power: 7 Major Companies .....	66
An Assessment of Pharma Industry Pipelines: Anticipated Launches to 2011e .....	67
Industry Summary: Launches, Peak Sales, and NPV by Year .....	67
Launch Expectations Over Time: Comparison of Lehman's 2004-2007 Estimates .....	67
Number of Drugs by Phase of Development, 2002-2007 .....	68
Breakdown of R&D Portfolio by Size .....	68
New Cancer Therapeutics and Vaccines Entering Clinical Study, 1993-2006 .....	68
Composition of New Cancer Therapeutics, 1990 and 2006 .....	68
Number of Annual New Drug Launches Projected for 62 Selected Companies in Lehman Universe, 2001-2011e .....	69
The Pharmaceutical Pipeline: A December 2007 Analysis .....	70
Compounded Growth by Stage of Development, 1999-2007 .....	70
Compounded Growth by Therapeutic Category: May 1995-November 2007 .....	70
Preclinical Compounds in Development, May 1998-November 2007 .....	70
Phase 1 Compounds in Development, May 1998-November 2007 .....	70
Phase 2/3 Compounds in Development, May 1998-November 2007 .....	71
Phase 3b/4 Compounds in Development, May 1998-November 2007 .....	71
An Assessment of Oncology Market and Pipeline .....	71
Novartis Looks to Build on New Growth Cycle in Pharmaceuticals in 2008 .....	72
Novartis vs. Leading Pharmas, Number of 2007 Drug Approvals and Success Rates, 2000-2007 .....	72

The Novartis Clinical Pipeline .....	72
Novartis Clinical Pipeline by Phase and Therapeutic Area, September 2007 .....	73
The DELPHI Model .....	73
Tufts CSDD Study on the Value of Follow-on Drugs and Indications .....	73
Roche Moves Ahead to Further Expand Innovation Capacity and Personalized Medicine Focus .....	74
The Roche R&D Model: Previous vs. New Model .....	74
The Roche Pipeline, 2007 vs. 2006 .....	75
Roche’s Clinical Development Pipeline by Therapeutic Area, February 2008 .....	75
More than 2,700 Drugs in US Clinical Development .....	75
Finding Biomarkers as Difficult as Finding New Drugs—Roche’s Humer .....	75
Merck Updates Its “Plan to Win” and New Operating Model .....	76
Merck R&D Pipeline, 2002 vs. 2006 vs. 2008 .....	76
Key Clinical Study Cycle Time Intervals: Merck vs. Peers .....	77
FDA Clears First Molecular Test to Profile Genetic Activity .....	77
Genetic Tests Could Accompany One in Five R&D Drugs Within Next Decade—Medco .....	77
AstraZeneca Reports Progress on Strategy to Strengthen its R&D Pipeline .....	78
AstraZeneca Candidates Entering Development, 2002-2007 .....	78
AstraZeneca First-time-in Man Projects, 2002-2007 .....	78
The AstraZeneca Pipeline, 2004-2007 .....	78
AstraZeneca Delivers Early Portfolio Faster, 2006-2010 Target .....	79
AstraZeneca’s New Productivity Targets for MedImmune .....	79
Pfizer Accelerates and Refocuses Its Pipeline .....	80
The Pfizer R&D Pipeline .....	80
Pfizer Projections on Rebuilding the Phase 3 Portfolio .....	80
Pfizer’s Biotherapeutics R&D Pipeline, 2008 .....	80
Phase 2 and 3 Success Rates: Pfizer vs. Industry .....	81
Pfizer’s Phase 3 Success Rates, 2005-2007 .....	81
Clinical Study Timelines: Pfizer, Industry-wide Medians, Best-in-Class Performance .....	81
Lilly Unveils Transformation Plan to Focus on Personalized Medicine .....	82
Prasugrel: Tailoring by Patient Characteristics .....	82
Lilly: From FIPCO to FIPNET .....	82
Lilly’s New Drug Launch Goals, 2008-2014 .....	83
Lilly NMEs in Clinical Development, 2000-2011 .....	83
Lilly’s Clinical Portfolio, Year-end 2007 .....	83
GSK Highlights R&D Pipeline and CEDDs Model, Looks to Biopharm and Asia .....	83
GSK vs. 11 Other Leading Pharmas, Mid- to Late-Stage Pipeline .....	83
The GSK Clinical Pipeline .....	84
GSK Tops Lehman Brothers Pharma Replacement Power Rankings .....	84
Bristol-Myers Squibb: Evolving to the “Next Generation BioPharma Model” .....	85
BMS Disease Areas and Unmet Medical Need .....	85
US NME Approvals by Review Status: BMS vs. Leading Companies .....	86
BMS vs. Industry Trends: Pharma R&D Spend and NME Approvals .....	86
Incremental R&D: A 2004 Study .....	87
Share of Follow-on Drugs Reaching R&D Milestones at Time of First-in-Class Approval .....	87
Share of Follow-on Drugs Reaching Clinical Milestones Prior to First-in-Class Reaching Same Milestone .....	87
Effective Market Exclusivity for First-in-Class Drugs, 1970s-1998 .....	87
The Effect of Follow-on Approvals on Drug Prices .....	87
FDA Therapeutic Ratings for Follow-on Drugs .....	87
PhRMA’s Medicines in Clinical Development Series .....	88
Analysis of Drugs in Clinical Development for Cancer by Development Status and Indication, 2008 .....	88
Analysis of Drugs in Development for Neurological Disorders by Development Status and Indication, 2008 .....	88
Analysis of Drugs in Development to Treat Rare Illnesses, 2007 .....	88
Analysis of Drugs in U.S. Clinical Development to Treat Mental Illnesses, 2006 .....	89
Analysis of Drugs in U.S. Development for Heart Disease and Stroke, 2007 .....	89
Analysis of Drugs in U.S. Clinical Development for Diseases of Aging, 2005 .....	89
Analysis of Drugs in U.S. Development for AIDS and AIDS-Related Illnesses, 2007 .....	89
Analysis of Drugs in U.S. Clinical Development to Treat Pediatric Illnesses, 2007 .....	90
Analysis of Drugs in U.S. Clinical Development for Women by Development Status and Indication, 2007 .....	90

Analysis of Drugs and Vaccines in U.S. Clinical Development for Infectious Diseases, 2007 .....	90
Embryonic Stem Cells to Enter Clinical Trials in 2008? .....	90
Leading Pharmaceutical Company R&D Profiles .....	91
GlaxoSmithKline .....	91
Pfizer .....	92
Schering-Plough .....	93
Biogen Idec .....	93
Astellas .....	94
Bristol-Myers Squibb .....	94
Roche .....	95
Johnson & Johnson .....	95
Merck .....	96
Abbott .....	96
AstraZeneca .....	97
Bayer Schering Pharma .....	97
Eli Lilly .....	98
Amgen .....	98
Wyeth .....	99
Novartis .....	99
Sanofi-Aventis .....	100
Development Pipelines of Selected Leading Drug Companies: Number of Products by Stage of Development, March 2008 .....	101
Large and Small/Mid-Tier Pharmas Relying on Each Other for Growth .....	101
Origin of New US Drug Approvals, 2000-2006 .....	101
New Drug Clinical Trial Starts Surge at Top 10 Companies in 2003-2005 Period .....	102
AIDS Vaccine R&D Setback .....	102
FDA Reviewers Being Pressured into Approval Indecision—Vasella and Hassan .....	102
International Patenting of Pharmaceuticals and Biotechnology, 2004-2006: Top Innovators .....	103
Ranking of Top 30 Pharma/Biotech Patentees, 2006 .....	104
Innovating Beyond Pharma's Patent "Black Hole" .....	105
Industry "Black Hole": 28% of Aggregated Revenues Threatened by 2010+ .....	105
Bristol-Myers Squibb Innovation Plot .....	106
Schering-Plough Innovation Plot .....	106
Eli Lilly Innovation Plot .....	106
Merck Innovation Plot .....	106
Wyeth Innovation Plot .....	106
Pfizer Innovation Plot .....	106
<i>Biopharmaceuticals</i>	
Number of Biotechnology R&D Projects by Therapeutic Area, 2007 .....	107
Biotech Company Development Pipelines: Number of Development Projects by Phase of Development, March 2008 .....	108
Biotech Filling Pharma's Pipeline Gaps, But With Blockbusters? .....	109
An Assessment of the Biotech Pipeline .....	109
Cumulative Number of Biotech Products Approved by FDA, 1993-2007 .....	109
Biotechnology Pipeline: Number of Products in Clinical Trials and Late-Stage Trials .....	109
Biological Drugs: A Study of Additional Indications Approved Postlaunch in the US .....	110
Genetics, Genomics, Proteomics, and Now Epigenetics .....	110
Vaccines Entering Clinical Development Rise Only Modestly in 1990-2005 .....	111
Number of Anti-Infective Vaccines Entering Clinical Study, 1990-2004 .....	111
Target Organism Types for Vaccines Studied, 1990-2005 .....	111
Number of Vaccines in Clinical Trials by Phase of Development .....	111
Clinical Phase Transition Probabilities for Vaccines Entering Clinical Study, 1990-2005 .....	111
Development Project Pipelines for 19 Selected Leading Biotech Companies by Therapeutic Categories, March 2008 .....	112

### **Section 3: Drug Development Costs/Complexity, Development Time, and Success Rates**

#### *Costs/Complexity*

Recent Estimates of the Cost of Developing New Drugs, 2008 .....	115
Measures of Clinical Trial Costs and Complexity, 2005-2007 (TTC) .....	116
Mean Cost per Patient in Clinical Trials, 2005-2007 .....	116

Clinical Trial Complexity by Trial Phase, 2005-2007	116
Mean Cost per Patient in Clinical Trials by Therapeutic Area, 2005-2007	116
Clinical Study Complexity by Therapeutic Area, Phase I-IV, 2005-2007	116
Measures of Clinical Trial Costs, 2005-2007 (TTC)	117
Index of Mean Cost per Patient in Clinical Trials by Clinical Phase, 2005-2007	118
Index of Mean Cost per Patient in Clinical Trials by Country/Region	117
Index of Mean Cost per Patient in Clinical Trials by Therapeutic Area, 2005-2007, Phase I-IV	117
Mean Site Fees per Clinical Study by Phase, 2005-2007	117
Index of Mean Cost per Patient by Oncology Disease Group, 2005-2007	117
Indices of US Clinical Trial Costs per Patient, 2005-2007 (TTC)	118
Index of Mean Cost per Patient in Clinical Trials by Clinical Phase, US, 2005-2007	118
Index of Mean Phase I Cost per Patient in Clinical Trials by Therapeutic Area, US, 2005-2007	118
Index of Mean Phase II Cost per Patient in Clinical Trials by Therapeutic Area, US, 2005-2007	118
Index of Mean Phase III Cost per Patient in Clinical Trials by Therapeutic Area, US, 2005-2007	118
Index of Mean Phase IV Cost per Patient in Clinical Trials by Therapeutic Area, US, 2005-2007	118
Measures of Clinical Study Complexity, 2005-2007 (TTC)	119
Index of Clinical Study Complexity by Trial Phase, Worldwide, 2005-2007	119
Index of Clinical Study Complexity, US vs. Western Europe, Phase I-IV, 2005-2007	119
Index of Clinical Study Complexity by Year, Phase I-IV, Worldwide, 2005-2007	119
Index of Clinical Study Complexity by Therapeutic Area, Phase I-IV, Worldwide, 2005-2007	119
Mean Number of Unique Procedures per Patient by Phase, 2005-2007	119
Biomedical Research and Development Price Index, 1980-2013	120
Selected Health Care Inflation Data, 1998-2007	120
New Drug Development Spending and Costs: A 2008 Analysis	121
R&D Expenses Regressions	121
R&D Expenses by Therapy Area for All Phases	122
Avandia, Vytarin, and Surrogate Endpoints	122
An Analysis of Site Performance within a Clinical Study and its Effect on Cost	123
Sample Hypercholesterolemia Study	123
Average Across Multiple Sites (enrollments/referrals)	123
Average Across Multiple Sites (cost)	123
Lilly Moves Relationships with Successful Sites to the Next Level	123
The Effects of Growing Clinical Trial Protocol Complexity: A 2008 Analysis	124
Change in Procedures per Protocol, 1995-2005	124
Change in Protocol Eligibility Criteria, 1999-02 vs. 2003-06	124
Investigative Site Work Burden per Protocol, 1999-2005	124
Protocol Design Impact on Study Conduct Cycle Times	124
Protocol Design Impact on Patient Recruitment and Retention Rates, 1999-02 vs. 2003-06	125
Percent Change in Grant Dollars per Protocol Procedure, 1999-2005	125
Study-Related Burdens vs. Compensation for Clinical Trial Sites, 2000-2005	125
An Analysis of Ways to Reduce Central Recruitment Costs	126
Probability of Randomizing Relative Average	126
Price Per Randomized for an Average Study by Recruitment Timeline	126
Price per Randomized for an Average Study by FOV Rate	126
US Clinical Site Profitability: A 2007 Assessment	127
Average Site Expenditures, 2004 vs. 2007	127
EDC Adoption in Clinical Trials: A 2008 Analysis	127
The FDA Amendments Act of 2007: An Analysis of Possible Effects on Phase 4 Clinical Trials and the CRO Market Opportunity	128
Lehman Analysis of Drug Approval and Post-marketing Commitment Trends, 1990-2006	128
Increase in PMCs Driven by More Conditional Approvals, 1997-2006	128
Lehman Analysis of Post-marketing Commitment Protocols, 2004-2007	129
Segmentation of US Clinical Trials by Therapeutic Area (TTC)	130
Industry Postmarketing Study Commitments: A 2007 Study	131
New Molecular Entity and Biologics Approvals with Commitments to Conduct Postmarketing Studies	131
Completion Times of Delayed Postmarketing Studies	131
Comparative Times to Complete Clinical vs. Nonclinical Postmarketing Studies	131
Comparative Cost to Complete Clinical vs. Nonclinical Postmarketing Studies	131
Where Today's Clinical Trials Are Being Conducted: A Study of New FDA-Regulated Studies in 2007	132

Number of Investigators Signing 1572s Annually for FDA-Regulated Clinical Trials, 1995-2007	132
Number of Investigators Signing 1572s in Selected Countries: Year-over-Year Percentage Increase/Decrease	132
Number of Investigators Completing 1572s to Participate in FDA-Regulated Clinical Studies by Country in 2007	133
Location of FDA International (ex-US) Clinical Investigator Inspections, 2007	133
Active Clinical Trials by Phase and Country/Region: A 2008 Analysis	134
Clinical Studies Openly Recruiting by Phase and Region	134
Number of Clinical Trials Initiated Annually for U.S. Submissions: FDA Estimates	134
Analysis of Paying Clinical Study Subjects	135
Average Payment to Research Subjects by Phase	135
Clinical Trials Move Abroad: Chasing Patients	135
Global Patient Recruitment (Patients Enrolled per Site): Five Regions Compared	135
Geographic Locale of Active Clinical Investigators, 1997-2007E	135
The Globalization of Clinical Trials: Number of Recruiting Studies by Country	136
Recruiting Clinical Studies by Region: Percent of Recruiting Studies	136
Clinical Studies by Country: Number of Recruiting Studies, 2007	136
Speed of Patient Recruitment: A Ten-Country Comparison	137
Clinical Trial Cost-Competitiveness: India, China, and Africa vs. US/Europe	137
Patient Recruitment Metrics at Pfizer	137
Demographics of Clinical Trial Populations: A Look at NIH Trials, 2007	138
Aggregate Enrollment Data for All Extramural and Intramural Research Protocols in FY2006 by Race and Gender	138
Aggregate Enrollment Numbers for All Extramural and Intramural Research Protocols Reported in FY2006, by Ethnicity	138
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2007	139
Key Clinical Trial Enrollment Statistics for NMEs Approved in 2000-2007	139
Clinical Trial Enrollments for Selected NMEs Approved in 2007	139
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2006	140
Key Clinical Trial Enrollment Statistics for NMEs Approved in 2000-2006	140
Clinical Trial Enrollments for Selected NMEs Approved in 2006	140
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2005	141
Key Clinical Trial Enrollment Statistics for NMEs Approved in 2000-2005	141
Clinical Trial Enrollments for Selected NMEs Approved in 2005	141
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2004	142
Key Clinical Trial Enrollment Statistics for NMEs Approved in 1999-2004	142
Clinical Trial Enrollments for Selected NMEs Approved in 2004	142
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2003	143
Key Clinical Trial Enrollment Statistics for NMEs Approved in 1999-2003	143
Clinical Trial Enrollments for Selected NMEs Approved in 2003	143
Emerging Clinical Trial Enrollment Benchmarks: Trial Size Statistics for New Drugs Approved in 2002	144
Key Clinical Trial Enrollment Statistics for NMEs Approved in 1998-2002	144
Clinical Trial Enrollments for Selected NMEs Approved in 2002	144
A 2007 Assessment of the Clinical Trial Experience: Volunteer Experiences, Study Enrollment, Consent Form Comprehension, and Study Dropout Rates	145
Would You Participate in a Clinical Trial Again?	145
Type of Support Received by Study Volunteers, 2006 vs. 2007	145
How Did you First Contact the Study Center?	146
Who Reviewed the Informed Consent Form With You?	146
Emerging Markets Not a Solution to Rising R&D Costs—Vasella	146
US Clinical Trial Sites Rate Sponsors: A 2007 Assessment	147
Highest Frequency as a Top 3 Rated Sponsor Across 29 Relationship Attributes	147
General Project Management Attributes	147
Quality of the Study Initiation Process	147
Quality of Ongoing Study Support	147
Quality of the Grant Payment Process	148
The Case for New Drugs and Better Predictive Biomarkers	149
A 2007 Assessment of the Site Management Organization Space	149
Number of SMOs Worldwide	149
Assessing the Cost to Develop a New Biotech Product	150
Pre-Approval Cash Outlays and Time Costs per Approved New Biopharmaceutical	150
Pre-Approval Cash Outlays per Approved New Molecule	150
Pre-Approval Capitalized Cost per Approved New Molecule: Biotech vs. Pharma	150

Capitalized Preclinical and Clinical Period Costs per Investigational Biopharmaceutical Compound .....	150
Medical Imaging Emerges in Clinical Trials: A 2007 Assessment .....	151
Size of the Medical Imaging Market, 2004-2009 .....	151
The Medical Imaging Market: Analysis of Various Techniques, 2005-2009P .....	151
Estimating the Cost of New Drug Development: Is It Really \$802 Million .....	152
Average Out-of-Pocket Clinical Costs for Investigational Compounds .....	152
Average Phase Time and Clinical Capitalized Costs for Investigational Compounds .....	152
Capitalized Preclinical, Clinical, and Total Cost per New Drug, in Millions of 2000 Dollars .....	153
Probability of Market Entry, Durations, and Costs for New Drugs by Firm .....	154
Probability of Market Entry, Durations, and Costs for New Drugs, by Disorder and Primary Indication .....	155
Achieving High Performance in Pharmaceuticals: Reversing the R&D Productivity Decline .....	156
R&D Productivity Challenge: Spend vs. Value (Sales) .....	156
Pharmaceutica R&D Expenditure, Average R&D Expenditure per NAS and Average ROI per NAS—Indexed four 7 year periods 1988-2000 .....	159
Average Number of Patients per Trial, by Phase and Therapeutic Area: A 2006 Assessment .....	160
Mean Number of Patients per Trial: Phase 1 Studies, by Therapeutic Area .....	160
Mean Number of Patients per Trial: Phase 2 Studies, by Therapeutic Area .....	160
Mean Number of Patients per Trial: Phase 3 Studies, by Therapeutic Area .....	160
Finding Biomarkers as Difficult as Finding New Drugs—Roche’s Humer .....	160
Average Per-Patient Clinical Trial Costs: A 2006 Assessment .....	161
Average Per-Patient Clinical Trial Cost Across Therapeutic Areas .....	161
Mean Phase 1 Per-Patient Clinical Trial Costs, by Therapeutic Area, US .....	161
Mean Phase 2 Per-Patient Clinical Trial Costs, by Therapeutic Area, US .....	161
Mean Phase 3 Per-Patient Clinical Trial Costs, by Therapeutic Area, US .....	161
Mean Phase 4 Per-Patient Clinical Trial Costs, by Therapeutic Area, US .....	161
The Global Clinical Trial Landscape: A 2006 Assessment .....	162
Delays in Clinical Development, 1995-2005 .....	162
Investigators Actively Participating in FDA-Regulated Clinical Trials, US vs. Foreign, 1996-2006 .....	162
Distribution of Investigators Outside North America Actively Participating in FDA-Regulated Trials, 1996-2006 .....	162
Annual Growth in Clinical Investigators Participating in FDA-Regulated Clinical Trials by Select Countries, 1995-2006 .....	162
Growth in Clinical Investigators Participating in FDA-Regulated Trials for Selected Countries .....	163
Global Turnover Among Active Investigators: “Drop Out” Investigators in US and Abroad by Level of Experience .....	163
Clinical Study Cost Comparisons by Country .....	163
Average Patient Enrollment Duration for Phase II and III Clinical Trials in Six Regions: Asia, Eastern Europe, Western Europe, Australia, South America, and US .....	163
Emerging Markets’ Cost and Enrollment Advantages: India and China vs. US .....	164
Clinical Sites in ROW Represent 20% of Sites Under US INDs .....	164
The Cost of Attrition in Drug Development .....	164
Addressing the Investigator Shortfall .....	165
The Widening Gap: More New Investigators, But Many More Studies, 1981-2005 .....	165
Top Five Reasons Physicians Don’t Refer Patients Into Clinical Trials .....	165
Measures of Investigator Participation in Trials .....	165
Clinical Research Offshoring: A Country Attractiveness Index for Clinical Trials .....	166
Number of Studies by Top 12 Pharma Countries by U.S.-Only and Non-U.S. Sites .....	166
Top 12 Pharma Companies as a Percentage of Total Industry Studies .....	166
Top 15 Most Common Locations for Clinical Trials Outside the U.S.: Number of Studies Sponsored by Pharmas in Each Country .....	166
Percentages and Numbers of Industry Studies and Offshore Locations .....	167
Overall Country Attractiveness Index .....	167
Overall Patient Availability Score by Country .....	167
Overall Indexed Clinical Trial Costs .....	167
Various Clinical Trial Metrics: Number of Sites, Patients per Phase .....	169
Average Number of Sites by Phase .....	169
Patients-per-Site Ratios by Phase .....	169
Average Number of Patients by Phase .....	169
Average Per-Patient Clinical Trial Cost by Phase .....	169
Average Per-Patient Clinical Trial Cost by Therapeutic Area and Trial Phase .....	169
Estimates of Nonclinical Study Costs and Durations .....	170
Clinical and Total R&D Costs by Therapeutic Category .....	171

Mean Clinical Phase Costs for Investigational New Drugs by Therapeutic Category .....	171
Mean Clinical Cost per Approved New Drug by Therapeutic Category .....	172
The Price of Innovation: New Estimates on Drug Development Costs .....	173
Average Out-of-Pocket Clinical Period Costs for Investigational Compounds .....	173
Average Phase Times and Clinical Period Capitalized Costs for Investigational Compounds .....	173
Trends in Capitalized Preclinical, Clinical, and Total Cost per Approved New Drug .....	174
Compound Annual Growth Rates in Out-of-Pocket and Capitalized Inflation-adjusted Cost per Approved New Drug .....	174
Out-of-Pocket Clinical Period Phase Costs for Approved Compounds .....	174
Out-of-Pocket and Capitalized Total Cost per Approved New Drug for New Drugs and for Improvements to Existing Drugs .....	174
Tufts Center for the Study of Drug Development Estimate of Cost to Develop a New Drug .....	175
Total Mean Costs to Develop a New Drug .....	175
The Costs of Drug Development: The Public Citizen Rebuttal .....	176
DiMasi Rebuttal to Public Citizen Critique .....	176
The Phase I Clinical Study Market: A 2007 Assessment .....	177
Phase I Still Stands Out: Projected Spending by Phase (U.S. \$ in billions) .....	177
The Phase IIIb/IV Market: A 2006 Assessment .....	178
Spending on Various Drug Development Phases, 2005-2009p .....	178
The Central Laboratory Market: A 2006 Assessment .....	179
Projected Central Laboratory Market, 2004-2009 .....	179
2005 Revenue from Companies with Central Laboratory Services .....	179
Clinical Trial Laboratory Services Market Share .....	179
Top Disqualification Categories for Study Candidates Sourced by Data-Based Patient Recruitment Strategies .....	180
Top 5 Reasons for Study Candidate Disqualifications Across 18 Therapeutic Areas .....	180
Top Disqualifications for Migraine .....	180
Top Disqualifications for Depression .....	180
Top Disqualifications for Anxiety .....	180
Top Disqualifications for Asthma .....	180
Top Disqualifications for Insomnia .....	180
Top Disqualifications for Fibromyalgia .....	180
Clinical Trial Recruitment Best Practices and Performance Benchmarks: The Wise Investments Survey .....	181
Source of Enrollment Delays .....	181
Enrollment Costs by Therapeutic Area .....	181
Patient Recruitment Budget Allocations, US vs. Non-US Sites .....	181
Performance Benchmarks .....	181
Percent of Recruitment Resources Applied to Planning vs. Rescue Intervention .....	182
Company Experiences based on When They Address Patient Recruitment Issues .....	182
Patients Enrolled per Site per Month .....	182
Average Months Delay per Trial Launched .....	182
Typical Contracting Time Required by Practice Setting .....	182
Reliance on Local & Central IRBs—Accuracy & Acceleration .....	182
Sources of Enrolled Patients—Phase III .....	183
Enrollment Impact of Recruitment Tactics .....	183
The Impact of Internet-based Clinical Trials on the Efficiency of Data Entry, Monitoring, and Data Management: A 2006 Case Study .....	184
Cumulative Frequency for Data of Initial Entry to Last Form Modified by the Study Site .....	184
Cumulative Frequency From the Day the Form Was Last Modified to CRA Review .....	185
Cumulative Frequency From the Date of CRA Review to In-House Form Review .....	185
<i>Development Time</i>	
Analysis of U.S. New Drug Development Process by Average Time to Complete Each Phase of Product Development, 2008 .....	186
New Drug Development Times: A 2007 Analysis .....	187
Mean Clinical and Approval Times: 1994-2006 .....	187
Mean Clinical and Approval Phase Lengths by Therapeutic Class, 2002-2006 .....	187
Cancer Therapy Development Times vs. Other Drugs: A 2007 Study .....	187
Clinical and FDA Approval Phases for New Cancer Therapeutics .....	187
Development Phase Lengths for Selected Therapeutic Categories .....	188
Development Phase Lengths and Attrition Rates for Selected Therapeutic Categories .....	188

The FDA's Fast Track Program: Effect on Review Time and Approval Success	189
Number and Total Approval Time (in months) of Approved NDAs and BLAs, by Fiscal Year of Submission, and by Review Procedure	189
Delays in Study Enrollment Timelines: A 2007 Assessment	190
Distribution of Delays in US Site Enrollment Timelines	190
Distribution of Delays in Site Enrollment Globally: US, Europe, Latin America, and Asia Pacific	190
Factor Most Often Causing Study Delays	190
Biopharmaceutical Development Times: A 2007 Analysis	191
Mean Biopharmaceutical Development Times: Clinical Phase, Approval Phase, and Total Phase Lengths, 1982-2006	191
Top Factors Causing Clinical Study Delays: A 2007 Survey	191
Top Factors Delaying Study Progress	191
The FDA on Study Initiation Delays	191
The Speed Demons of Drug Development: Achieving Revenue Gains and Cost Savings	192
Fastest Development Companies: Median Clinical Development and Regulatory Cycle Times, 2000-2005	192
Median Time from IND Filing to NDA Approval for Nine Therapeutic Areas, 2000-2005	192
Median Clinical Development Time and Regulatory Cycle Times: All Companies vs. Fastest 10 Companies	192
Standard Deviations and Coefficients of Variation for Drugs Approved Between 2000 and 2005	192
Fastest vs. Slowest Firms: Percentage of Terminated Projects by Phase, 1994-2005	193
Drugs of Fastest vs. Slowest Companies: Comparative Development and Regulatory Cycle Times and Revenue Advantage, 2000-2005	193
Emerging Markets' Cost and Enrollment Advantages: India vs. China vs. U.S	193
Development Times for Biotech vs. Drug Products: A 2006 Study	194
Clinical Development and Approval Times: Biopharmaceuticals vs. Drugs	194
Time Consumed by Various Clinical Trial Activities	194
Study Sites' Perception on Reasons for Study Delays	194
Factor Most Often Causing Clinical Study Delays	194
Clinical and Approval Timelines for Drugs Approved 1984-2004	195
Clinical and Approval Phases for New Drugs, 1984-2004	195
Mean Clinical Phase Times for Priority and Standard NCEs Approved, 1984-2004	195
Mean FDA Approval Times for Standard and Priority NCEs, 1984-2004	195
Mean Clinical Phase Times for NCEs Approved by Therapeutic Area, 1996-2004	195
Mean Clinical and Approval Phase Lengths by Therapeutic Class, 2002-2004	196
Share of NCE Approvals by Location of Original Marketing, 1987-2004	196
Number of NCE Approvals, 1984-2004	196
Are Development Times for Pharmaceutical Companies Increasing or Decreasing?	197
Sample of Development Times for 25 Drugs	197
Pharmaceutical Development Times, by Category	198
Total Post-IND Development Period, Clinical Trial Period, and Regulatory Review Periods, by Year of NDA Approval, 1992-2001	199
Total Post-IND Development Period, Clinical Trial Period, and Regulatory Review Period, by Year of IND Filing, 1985-1995	200
Clinical and Approval Timelines for Biopharmaceuticals Approved in the US, 1996-2005	201
Comparison of Mean Clinical and Approval Phase Lengths for Biopharmaceuticals Approved, 1996-2000 vs. 2001-2005: All, Orphan, and Priority Biopharmaceuticals	201
Comparison of Mean Clinical and Approval Phase Lengths for Biopharmaceuticals Approved, 1996-2000 vs. 2001-2005 for Top Therapeutic Categories: Oncology, Endocrine, and Immunology	201
Total Development Times for Drug and Biopharmaceutical Products, 1985-2004	202
Mean Total Development Times for Drugs and Biological Products Approved in the United States, 1994-2004	202
The FDA's Fast Track Program: Its Utilization and Impact on Drug Development Times: An April 2006 Update	203
Cumulative Fast Track Designations Granted by CDER and CBER, 2000-2006	203
Fast-Track Designations by Disease Type, 2001-2005	203
Reasons for Development Problems in Fast Track Programs	203
Total Development and Approval Times by FDA Program	203
Mean Development Times for Fast Track Products by Therapeutic Area, 1998-2005	204
The Effects of CRO Usage on Drug Development Times	204
Days that Actual Submission Exceeded Projected Submission Date, Low vs. High CRO Usage Projects	204
Mean Time to Four Pivotal Clinical Trial Milestones, Low vs. High CRO Usage Projects	204

A Measure of Quality: Case Report Form Queries/Page Screen .....	204
Quantifying the Time Used in Key Clinical Study Activities: A 2006 Assessment .....	205
Percent of Site Personnel Time by Research Study Activity .....	205
Site Personnel Time: Minutes/Activity for Common Study Activities .....	205
Ten Most Time-consuming Activities .....	205
The Duration of Clinical Trials by Phase and Therapeutic Area: A 2004 Study .....	206
Clinical Trial Duration by Phase .....	206
Phase I Clinical Trial Duration by Therapeutic Area .....	206
Phase II Clinical Trial Duration by Therapeutic Area .....	206
Phase III Clinical Trial Duration by Therapeutic Area .....	206
Clinical Trial Components by Percent of Total Trial Timeline Consumed .....	206
Pharmaceutical Development Phases: A Duration and Success Rate Analysis .....	207
Phase I, II, and III Clinical Trial Durations by Successful and Failing Projects: Summary Descriptive Statistics .....	207
Crude Probability of Success (and Phase Durations, in months) for Successful Drugs by	
Company Size, Type of Product, Dosage Form, and Therapeutic Category .....	207
Crude Probability of Failure (and Phase Durations, in months) for Failing Drugs by	
Company Size, Type of Product, Dosage Form, and Therapeutic Category .....	208
Various New Drug Development Metrics .....	209
Number of NMEs First Marketed 1992-2003 and Their Mean Development Time .....	209
Trends in Clinical Development Times: Various Milestones, 1997-2003 .....	209
Composite Median Cycle Times for NASs in Development, 1997-2003 .....	209
Development Times for All New Active Substances in R&D Between 2000 and 2002 .....	209
The FDA's Fast Track Program: A 2005 Analysis .....	209
Drug Development Times .....	209
Biological Product Development Times .....	210
Fast Track Designation Requests .....	210
Percent of Fast Track Designations and Approvals by Type of Product: Biological or Chemical .....	210
Reasons for "Fast Fail" .....	210
The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade After Passage of PDUFA .....	211
Mean NCE Clinical, Approval, and Total Phase Lengths for NCEs Approved in 1999, 2000, and 2001 .....	211
Median Clinical and Approval Phases for New Chemical Entity Approvals in 1999, 2000, and 2001 .....	211
Mean Clinical and Approval Phases in Years for NCEs Approved in Each of Last Six Three-Year Periods .....	211
Mean Clinical and Approval Phases for NCEs Grouped by Therapeutic Classes .....	211
Mean Clinical Phases in Years for NCEs Grouped by Therapeutic Class in Each of	
the Last Three-Year Periods .....	211
Mean Clinical, Approval, and Total Phases in Years for NCEs Approved in 1999-2001	
and Designated as Accelerated Approval, Fast Track Approval, or Both, Compared	
with Those for All Other NCEs and with Orphan Approvals .....	212
Percentage of NCEs First Approved in the United States and Those with Various	
Periods of Prior Foreign Marketing .....	213
Percentage of NCEs First Approved in the United States, and Those with One or	
More Years of Prior Foreign Marketing, in Each of the Last Five Three-Year Periods .....	213
<i>Success Rates</i>	
A 2008 Analysis of Approval Success Rates by Product Type and Novelty .....	214
NME Success Rates by Compound Type, 1997-2007 .....	214
NME Success Rates by Target Type, 1997-2007 .....	214
Product Type and Target Novelty, 1997-2008 .....	214
NME Success Rates by Compound Type, 2002-2007 .....	214
NME Success Rates by Target Type, 2002-2007 .....	214
Product Type and Target Novelty, 2002-2007 .....	214
A 2008 Analysis of the Mid- and Late-Stage R&D Pipeline: Size, Developer Type, Indications, and Success Rates .....	215
Number of Drugs in Phase 2-Pre-Registration by Developer Type, 1997-2007 .....	215
Number of Indications per Drug in Phase 2-Pre-Registration by Developer Type for Select Years, 1997-2007 .....	215
Likelihood of Approval by Phase for Large Company Products, 2000-2007 .....	215
Likelihood of Approval by Phase for Small Company/Institution Products .....	215
The Pipeline and the New Realities of Drug Development .....	215
Development Attrition Rates for Selected Therapeutic Categories .....	216
Development Attrition Rates for Selected Therapeutic Categories .....	216

Emerging Success Rates for New Cancer Therapies, 1990-2006 .....	217
New Cancer Therapeutics and Vaccines Entering Clinical Study, 1993-2006 .....	217
Clinical Phase Transition Probabilities for Cancer Therapeutic Candidates .....	217
Almost Nothing Getting Through FDA Now—Wyeth’s Ruffolo .....	217
Smaller Companies and Biotechs More Reluctant to Discontinue R&D Projects—Pazdur .....	217
FDA Approvals and Phase III Failures: Pharma vs. Biotech .....	218
Attrition Rates in Drug Development Phases .....	218
An Analysis of Late-Stage Success Rates: Biotech Products versus Pharmaceuticals .....	219
Success Rates of Late-Stage Clinical Trials in Biotechnology, 1995-2006 .....	219
FDA Actions on Biotechnology Product Applications by Nature of Action, 1995-2006 .....	219
Probability of Success to Market for New Active Substances by Origin: Self-Originated vs. Licensed-in .....	219
Kola on Emerging Attrition Rate Trends, 2007 .....	220
Estimates of Drug Success Rates: Unprecedented vs. Precedented Molecules .....	220
Drug Success Rates: Unprecedented vs. Precedented Molecules .....	220
Major Culprits in Drug Approvals and Late-Stage Trial Delays .....	220
Comparative Success Rates for Biotech vs. Drug Products: A 2006 Study .....	221
Transition Probabilities for Clinical Phases: Biopharmaceuticals vs. Drugs .....	221
Fastest Pharma Firms Kill Development Projects Sooner .....	221
Fastest vs. Slowest Firms: Percentage of Terminated Projects by Phase, 1994-2005 .....	221
FDA Reviewers Being Pressured into Approval Indecision—Vasella and Hassan .....	221
Emerging FDA Approval Standard Creating Monopolies—Wyeth’s Essner .....	221
New Drug Success Rates at Top 10 Pharma Companies: A 2006 Study .....	222
Phase Transition Probabilities for Self-Originated Drugs of Leading Firms .....	222
Phase Transition Probabilities by Therapeutic Class for Relatively High Success Rate Classes .....	222
Phase Transition Probabilities by Therapeutic Class for Relatively Low Success Rate Classes .....	222
Clinical Approval Success Rates by Therapeutic Class .....	222
Success to Market Rates for New Active Substances: Comparison of Chemical Entities and Biotech Products .....	223
Probability of Success to Market for New Active Substances: Comparison of Therapeutic Areas .....	223
New Postapproval Requirements Less Harmful to Pharma R&D Than New Preapproval Burdens—Analysis .....	223
Can the Pharmaceutical Industry Reduce Attrition Rates? .....	224
Success Rates by Therapeutic Area .....	224
Success Rates from First-in-Man to Registration .....	224
Success Rates by Stage of Development .....	224
Reasons for Attrition .....	224
Drug Success Rates: A 2003 Assessment .....	226
Probability of FDA Approval for New Drugs Entering a Clinical Phase by Therapeutic Category .....	226
Distribution of Research Terminations by Therapeutic Category .....	226
Probability of New Drugs Entering a Phase by Therapeutic Category .....	226
Drews on Pharma Industry Productivity and Strategic Trends in the Drug Industry .....	227

## **Section 4: Regulatory/FDA Statistics**

### *INDs*

Number of IND Submissions, 1982-2007 .....	229
Breakdown of Drug Divisions’ Active IND Review Workload as of Year-End 2007 .....	229
Number of Active INDs at the Close of the Calendar Year, 1983-2007 .....	229
Breakdown of CDER Divisions’ Workload by INDs Received in 2007 .....	230
CDER Holds on Commercial IND Submissions, 1990-2006 .....	230
Clinical Holds on Commercial IND Submissions by Division, 2006 .....	230

### *NDA*s

Number of NDAs Pending at the Close of the Calendar Year, 1983-2007 .....	231
Breakdown of Drug Divisions’ Pending NDA Review Workload, Year-End 2007 .....	231
Breakdown of Drug Divisions’ Workload by NDAs Received in Fiscal Year 2007 .....	231
Breakdown of Divisions’ Workload by Pending NDA Supplements, Year-End 2007 .....	232
CDER Refusal-to-File (RTF) Actions by Year, 1994-2007 .....	232
Key Drug Submission and Approval Statistics, 1993-2007 .....	233
Number of NME Approvals and Approval Times, 1984-2007 .....	233
NME Review Time Ranges, 1995-2007 .....	234

Priority/Standard NME Review Gap, 1995-2007 (in months) . . . . .	.234
Median Approval Times for All NMEs by Calendar Year, 1986-2007 . . . . .	.234
Average NME Review Times in Months by CDER Division, 2005, 2006, and 2007 . . . . .	.235
Average NME Review Times in Months by CDER Division, 1993-2004 . . . . .	.236
Number of NDAs and NMEs Approved by Year, 1983-2007 . . . . .	.237
NMEs Approved Based on Therapeutic Potential, 1985-2007 . . . . .	.237
Percent of All Approved NDAs Receiving Priority Review Status, 1994-2007 . . . . .	.237
CDER’s Priority NME Approvals by Class of Drug, 1994-2007 . . . . .	.237
CDER-Wide First Action Performance for FY05, FY06, and FY07 User Fee Cohorts of NDAs, Resubmissions, Effectiveness Supplements, and Manufacturing Supplements . . . . .	.238
A 2008 Analysis of CDER First-Cycle Review Outcome Trends for NDAs, FY1996-FY2007 . . . . .	.239
Percent of Original NDAs Approved in First Review Cycle by Submission Cohort, FY1996-FY2007 . . . . .	.239
Percent of Standard/Priority Original NDAs Approved in First Review Cycle by Submission Cohort, FY1997-FY2007 . . . . .	.239
Percent of Original NDAs Receiving Approvable, Not Approvable, and Withdrawal Actions, FY1997 to FY2007 . . . . .	.239
An Analysis of Review Cycles to Approval for New Drugs . . . . .	.240
Summary Cycle to Approval Statistics for 2005-, 2006- and 2007-Approved NMEs . . . . .	.240
Distribution of Review Cycles to Approval, 2007, 2006, and 2005 . . . . .	.240
Benchmarking the Review Cycles for NMEs Approved in 2007 . . . . .	.241
Average Cycle Times for Approved NMEs, 2005, 2006, and 2007 . . . . .	.241
Mean Review Cycle Times for Approved Priority/Standard NDAs in the FY2000-FY2006 Submission Cohorts . . . . .	.242
FDA: Refusing Few NDAs, but Delaying More Clinical Trials . . . . .	.242
FDA “Barely Hanging On”—Hutt . . . . .	.242
A Closer Look at the FDA’s 50 Fastest Drug Approvals, 1963-2007 . . . . .	.243
Median Approval Times for Priority and Standard NDAs, 1993-2006 . . . . .	.245
Median Approval Times for Priority and Standard NMEs, 1993-2006 . . . . .	.245
Guardrails, Not Speedbumps, for FDA Drug Approval Process—FDA’s Von Eschenbach . . . . .	.245
A Comparison of FDA vs. EMEA Drug Approval Times, 2000-2005 . . . . .	.246
Mean Approval Times for New Substances Approved by EMEA and FDA, 2000-2005 . . . . .	.246
Time from Approval in First Market to Approval in Second Market . . . . .	.246
EU vs. US Approval Time for Orphan Drugs . . . . .	.246
“Risk Averse” FDA? A Look at What’s Being Approved . . . . .	.247
U.S. New Drug Approvals of 2007: NDA Review Times by Drug . . . . .	.247
U.S. New Drug Approvals of 2006: NDA Review Times by Drug . . . . .	.248
U.S. New Drug Approvals of 2005: NDA Review Times by Drug . . . . .	.248
U.S. New Drug Approvals of 2004: NDA Review Times by Drug . . . . .	.249
U.S. New Drug Approvals of 2003: NDA Review Times by Drug . . . . .	.250
U.S. New Drug Approvals of 2002: NDA Review Times by Drug . . . . .	.250
U.S. New Drug Approvals of 2001: NDA Review Times by Drug . . . . .	.251
U.S. New Drug Approvals of 2000: NDA Review Times by Drug . . . . .	.252
U.S. New Drug Approvals of 1999: NDA Review Times by Drug . . . . .	.253
U.S. New Drug Approvals of 1998: NDA Review Times by Drug . . . . .	.254
U.S. New Drug Approvals of 1997: NDA Review Time for Each Drug . . . . .	.255
U.S. New Drug Approvals of 1996: NDA Review Time for Each Drug . . . . .	.256
U.S. New Drug Approvals of 1995: NDA Review Time for Each Drug . . . . .	.257
U.S. New Drug Approvals of 1994: NDA Review Time for Each Drug . . . . .	.258
U.S. New Drug Approvals of 1993: NDA Review Time for Each Drug . . . . .	.259
U.S. New Drug Approvals of 1990, 1991, and 1992: NDA Review Times for Each Drug . . . . .	.260
New Analysis on Factors Associated with First-Cycle Approvals . . . . .	.262
Approval Cycle Percentage by Application Type . . . . .	.262
First-Cycle Approval Rates for Self-Originated vs. In-licensed Products . . . . .	.263
Percentage of Multi-Cycle Reviews by Sponsor Experience . . . . .	.263
Approval Rate vs. Sponsor Type and Origin . . . . .	.263
Key Deficiencies Cited in Action Letters . . . . .	.264
Effect of End of Phase 2 Meetings on Approval Rate . . . . .	.264
An Analysis of FDA’s Fast Track Initiative, 2008 . . . . .	.265
Industry’s Fast Track Designation Requests to CDER, FY1999-FY2007 . . . . .	.265
CDER’s Fast Track Program Activity . . . . .	.265

CBER's Fast Track Program Activity .....	265
Remembering the Good Old Delays .....	265
Postmarketing Study Commitment Trends for New Drugs: An Analysis of NMEs Approved in 2007 .....	266
Percent of NMEs Approved with Postmarketing Commitments, 2001-2007 .....	266
New Postapproval Requirements Less Harmful to Pharma R&D Than New Preapproval Burdens—Analysis .....	266
Safety-Based Drug Marketing Withdrawals in the United States, 1980-2008 .....	267
CDER Safety-Based Drug Withdrawals: Pre-PDUFA vs. PDUFA Era, 1971-2007 .....	268
Drugs Cleared New User-Fee Review Deadlines More Likely to Present Safety Issues? .....	268
Molecular “Nose” to Sniff Out Drug Safety Issues Earlier? .....	268
Faster FDA Drug Approval Times and Drug Withdrawals: A 2005 Analysis .....	269
Drug Safety Withdrawals and Withdrawal Rates by Decade .....	269
Rates of New Drug Approvals and Safety Based Withdrawals .....	269
Median Approval Times for Safety Withdrawals vs. All Drugs by Decade .....	269
Median Approval Times for Safety Withdrawals vs. All Drugs, by Therapeutic Class .....	269
Distribution of Safety Withdrawals by Therapeutic Class, 1980-2005 .....	269
Pediatric Study Costs and Complexity Levels Grow, 2000-2006 .....	270
Orphan Drug Activity Continues to Hit Record Levels in 2007 .....	271
Orphan Drug Designation and Approval Statistics, 1990-2007 .....	271
Prevalence of Orphan Drugs in CDER's NME Approvals, 2001-2007 .....	271
Is FDA Failing to Use Advisory Committees? .....	271
NDA's Approved Under CDER's Accelerated Approval Program, 1992-September 2007 .....	272
<i>Biologics</i>	
Summary of CBER Actions in 2007 .....	273
Key CBER Review Statistics for 2007 .....	273
CBER's New Biological Product Approvals for 2007 .....	273
Summary of CBER Actions in 2006 .....	274
Key CBER Review Statistics for 2006 .....	274
CBER's New Biological Product Approvals for 2006 .....	274
Summary of CBER Actions in 2005 .....	275
Key CBER Review Statistics for 2005 .....	275
CBER's New Biological Product Approvals for 2005 .....	275
Summary of CBER Actions in 2004 .....	276
Key CBER Review Statistics for 2004 .....	276
CBER's New Biological Product Approvals for 2004 .....	276
Summary of CBER Actions in 2003 .....	277
Key CBER Review Statistics for 2003 .....	277
CBER's New Biological Product Approvals for 2003 .....	277
Summary of CBER Actions in 2002 .....	278
Key CBER Review Statistics for 2002 .....	278
CBER's New Biological Product Approvals for 2002 .....	278
Summary of CBER Actions in 2001 .....	279
Key CBER Review Statistics for 2001 .....	279
CBER's New Biological Product Approvals for 2001 .....	279
Summary of CBER Actions in 2000 .....	280
Key CBER Review Statistics for 2000 .....	280
CBER's New Biological Product Approvals for 2000 .....	280
<i>Orphan Drugs</i>	
Orphan Drug Designation and Approval Statistics, 1990-2007 .....	281
Cumulative Growth of Orphan Drugs, 1984-2007 .....	281
Orphan Drug Approval Times vs. Approval Times of Other Drugs, 1993-2007 .....	281
Orphan Drug and Biologic Approvals, 1993-2007 .....	281
Orphan Drug and Biologic Approvals in 1990, 1991, and 1992 .....	283
<i>Over-the-Counter Drugs</i>	
Rate of Rx-to-OTC Switches per Year, 1951-2007 .....	283
<i>Generic Drugs</i>	
Generic Drug Approval Times: Median Time to Approval 1993 to 2007 .....	284
Pending ANDAs Continue to Surge at FDA, 2000-2007 .....	284

Mean and Median ANDA/AADA Review Times, 1995-2007	.284
Annual ANDA and AADA Submission and Approval Statistics, 1995-2007	.284
CDER Clinical Site Inspection Results, FY1997-FY2007	.285
CDER Clinical Investigator Inspections, FY92-FY2007	.285
CDER Inspections of Foreign Clinical Investigators, FY91-FY2007	.285
Clinical Investigator Deficiency Categories, FY2006	.285
Inspection Results for Clinical Investigators, FY2006	.285

## **Section 5: International Statistics**

### *European Union*

R&D Spending in Europe’s Pharmaceutical Industry, 1980-2007	.287
Pharmaceutical R&D Spending Within EFPIA Countries, 1990-2006	.287
Mean EMEA Review Time for Human Drugs Submitted Under the EC’s Centralized Procedure, 2007	.288
Mean EMEA Processing Time for Human Medicinal Products, 1997-2007	.288
Mean Processing Times for Key Stages of Centralized Process, 1996-2007	.288
Cancer, Anti-Infective, and Neurology Drugs Dominate New Centralized Submissions to EMEA in 2007	.288
Marketing Authorization Applications Rise to Record Levels at the EMEA	.289
Marketing Authorization Applications Undergoing Initial Evaluation, 2000-2007	.289
CPMP Initial Evaluation Opinions and Sponsor Withdrawals for New Medicines, 2000-2007	.289
An Analysis of the Mutual Recognition Procedure, 2007	.289
UK R&D and Clinical Trials to Plummet After Drug Pricing Scheme Scapped	.289
Comparison of FDA vs. EMEA Drug Approval Times, 2000-2005	.290
Mean Approval Times for New Substances Approved by EMEA and FDA, 2000-2005	.290
Time from Approval in First Market to Approval in Second Market	.290
EU vs. US Approval Time for Orphan Products	.290

### *United Kingdom*

Pharmaceutical Industry R&D Investment in the UK, 1989-2006	.291
The MHRA’s Clinical Trials Work (by CTX submissions), 2006/2007	.291
MHRA’s New Active Substances Assessed and Mean Assessment Times, 1993-2007	.291

### *Japan*

Pharmaceutical R&D Expenditures in Japan, 1985-2006 (in bill. Yen)	.292
Annual Number of New Chemical Entities Approved in Japan, 1983-2007	.292
Number of INDs for Investigational New Drugs Submitted in Japan, 1990-2006	.292
Success Rates of New Drug Development in Japan, 2002-2006	.292
R&D Expenditures of 20 Leading Japanese Pharmaceutical Manufacturers, 2003-2006	.293
Number of Prescription Drug Manufacture and Import Approvals Granted in Japan, 1985-2006	.293
Median NDA Approval Trends in Japan by Year of Submission, 1996-2005	.293
Number of Drugs in Development in Japan by Pipeline Stage and Disease/Therapeutic Category, 2008	.294
Addressing Japan’s “Drug Lag”	.295

### *Germany*

Pharmaceutical R&D Expenditures by German Drug Industry, 1999-2006	.295
Number of New Chemical Entities Approved in Germany, 1988-2006	.295

### *Canada*

Canadian Drugs Directorate New Active Substance (NAS) Approval Times, 1993-2007	.295
R&D Spending by Canadian Drug (Rx&D Member) Companies, 1984-2006	.296
New Drug Submission (NDS) Approval Times in Canada, 1997-2007	.296

### *Latin America*

Global Clinical Trials: A Focus on Latin America	.297
Number of Clinical Trials Conducted in Various Countries/Regions	.297
Clinical Studies in Latin America, by Country, Year-end 2007	.297
New Latin America Clinical Trials Posted on ClinicalTrials.gov by Country, 1999-2007	.298
Regulatory Timelines Associated with Clinical Trials in Latin America, 13 Countries	.298
Will Pharma Stop Drug Launches in the UK?	.298
Orphan Drugs Get Closer Look	.298

*Global*

Comparative R&D Spending, Sales, and Product Launch Trends Worldwide: A 2008 Analysis .....299

- Breakdown of World Pharma Market—2007 Sales .....299
- Pharmaceutical R&D Expenditure Annual Growth Rate, US vs. Europe, 1993-2007 .....299
- Pharmaceutical R&D Expenditure in Europe, the United States, and Japan, 1990-2007 .....299
- Opening and Closing of Research Sites in Europe, US, and Asia, 2001-2006 .....299
- Number of Compounds in Development by Country/Region: US, Europe, Japan, and ROW .....300
- U.S., European, Canadian, Japanese and Australian Biotech: Global Activity Measures, 2007 .....300

Clinical Research Market in Central and Eastern Europe: A 2007 Assessment .....300

- Comparative Global Clinical Trial Growth in Emerging Markets, 2002-2006 .....300
- Active Phase II-IV Sites in Eastern Europe/Russia .....300

Russia’s Clinical Trials Market Heats Up .....300

Trends in Worldwide Pharma and Biotech R&D Expenditures, 2002-2012P .....301

- Global R&D Spending by World’s Top 400 Pharma & Biotech Companies, 2002-2012 .....301

Trends in Worldwide R&D Expenditure, 1993-2008P .....302

Global New Active Substance Product Launches, 2007 .....302

Russia’s Clinical Trials Market: A 2007 Assessment .....303

- Clinical Trials Approved in Russia .....303
- Russian Patients Enrolled in Global Clinical Trials .....303
- Originating Country of Global Clinical Trials in Russia .....303
- Active Phase II-IV Sites in Eastern Europe/Russia .....303

India’s Clinical Research Market: A 2006 Assessment .....304

- India’s Participation in Global Trials Grows: Number of Indian Clinical Investigators for U.S. INDs, 2001-2005 .....304
- Number of Indian Investigators Participating in Global Trials, by City, 2002-2005 .....305
- U.S. NIH Grants to Indian Investigative Sites, 2000-2005 .....305

India to Need 50,000 Clinical Trial Pros by 2010? .....306

Unprecedented Chinese Government Investment to Boost Innovative Drug Development .....306

China’s R&D Goal: \$10B by 2010 .....306

China as a Site for Clinical Trials: A 2005 Assessment .....307

- China’s Participation in Global Clinical Trials Grows, 2001-2004 .....307
- Clinical Trial Approvals in China, 2001-2003 .....307
- Annual Number of Clinical Trials in Hong Kong, 1999-2004 .....308

Western Drugs Hard Sell in China? .....308

Singapore as Hub for Clinical Trials in Asia .....309

- Clinical Trial Certificates Issued in Singapore, 1998-2004 .....309
- Singapore Clinical Trials by Therapeutic Area, 2003-2004 .....309

Clinical Trials: Does East Cost Least? .....310

- Comparison of Phase II-III Costs per Patient as a Percentage of UK Costs Between 1995 and 2002 .....310
- Changes in Phase II-III Costs per Patient in Three Eastern European Countries as a Percentage of UK Costs .....310

Estimated Clinical Trial Applications Submitted per Year in Various European Countries .....310

Clinical Trials in Spain, 1994-2000 .....310

Regulatory Approval Times, 1998-2004: US, Japan, and EU .....311